• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Diquafosol sodium
Mango Powder
Nettles Leaf Extract
lutein
Bamboo Leaf Extract
TZ-SN01 Prefilled Single-nozzle Nasal Spray Device

Zydus Cadila gets final US FDA nod for Solifenacin Succinate Tablets

expresspharmaOctober 22, 2020

Tag: Zydus Cadila , FDA , Solifenacin Succinate Tablets

Zydus Cadila has received final approval from the USFDA to market Solifenacin Succinate Tablets, (US RLD: Vesicare Tablets) in the strengths of 5 mg and 10 mg.

Solifenacin Succinate is a symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 309 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Previous:Dr Reddy’s relaunch OTC Famotidine Tablets USP, 10 mg and 20 mg, in US

Next:Strides receives USFDA approval for Ethacrynic Acid Tablets

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Zydus Cadila gets final US FDA nod for Solifenacin Succinate Tablets | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Sirolimus (FDA)

Sirolimus (FDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Ivermectin (FDA)

Ivermectin (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service